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Pediatric lung transplantation 
The years 1985 to 1992 and the clinical trial of FK 506 
The application of lung transplantation to the pediatric population was a natural extension of the 
success realized in our adult transplantation program, which began in 1982. Twenty pediatric patients 
(age range 3 to 18 years) have had heart-lung (n = 11), double lung (n = 8), and single lung (n = 1) 
transplantation procedures. The causes of end-stage lung disease were primary pulmonary hypertension 
(n = 7), congenital heart disease (n = 5), cystic fibrosis (n = 4), pulmonary arteriovenous malformation 
(n = O~ graft-versus-host disease (n = 1), and desquamative interstitial pneumonitis (n = 1). Four (20 %) 
patients had thoracic surgical procedures before the transplantation operation. The survival was 80 % 
at a mean foUow-up of 2 years. Immunosuppressive drugs included cyclosporine (n = 9) or FK 506 
(n = 11) based therapy with azathioprine and steroids. Children were foUowed up by means of 
spirometry, transbronchial biopsy, and primed lymphocyte testing of bronchoalveolar lavage fluid. The 
mean number of treated episodes of rejection was 1.4 at 30 days, 0.5 at 30 to 90 days, and 1.4 at 
more than 90 days, and the first treated rejection episode occurred on average 28 days after the 
operation. Obliterative bronchiolitis developed in four (25 %) of 16 patients surviving more than 100 
days. Results of pulmonary function tests have remained good in almost aU recipients. The greatest 
infectious risk was that of cytomegalovirus: one death and one case of pneumonia. Posttransplantation 
Iymphoproliferative disease was diagnosed in two (12.5 %) patients; both recovered. The most common 
complications were hypertension (25 %) and postoperative bleeding (15 %). Early results indicate that 
lung transplantation is a most promising therapy for children with severe vascular and parenchymal 
lung disease. (J THORAC CARDIOVASC SURG 1993;105:337-46) 
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Heart and Lung Transplantation Registry as of 1991 had 
been performed since 1985, in over 90 centers worldwide.' 
As in cardiac transplantation, the application of pulmo-
nary transplantation to the pediatric age group has lagged 
behind the successes realized in the adult population. Less 
than 15% (n = 220) of all lung transplantation proce-
dures have been performed in patients under the age of 20 
years and only 4% (n = 60) in patients less than 10 years 
of age.' At the University of Pittsburgh, the first heart-
lung transplantation was performed in 1982, and it was 
not until 1985 that our program began accepting children 
as candidates. From 1985 through March 1992, 20 chil-
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Fig. 1. A decade of lung transplantation, 1982 to 1992, University of Pittsburgh Medical Center. 
dren «18 years) have undergone heart-lung, double 
lung, or single lung transplantation at Children's Hospi-
tal of Pittsburgh (CHP). The growth of our pediatric lung 
transplantation program has mirrored the national expe-
rience and that of our adult program, both in terms of 
increased organ availability and in the trend toward sin-
gle and double lung procedures and away from heart-lung 
transplantation (Fig. I). In this report we include our 
pediatric experience with emphasis on our present man-
agement strategies and the preliminary results of the 
clinical trial of FK 506 immunosuppression. 
Patients and methods 
Patient group. Twenty children, aged 3 to 18 years, have 
undergone heart-lung (n = 11), double lung (n = 8), or single 
lung (n = 1) transplantation from 1985 through March 1992. 
Seventeen (85%) of these children were female and three (15%) 
were male. The indications for transplantation have been 
primary pulmonary hypertension (n = 7), congenital heart dis-
ease (n = 5), cystic fibrosis (n = 4), pulmonary arteriovenous 
malformation (n = 2), graft-versus-host disease (n = 1), and 
desquamative interstitial pneumonitis (n = 1) (Fig. 2). The 
congenital heart anomalies in our five patients were transposi-
tion of the great arteries (n = 3) and ventricular septal defect 
(n = 2). 
Four (20%) of the twenty recipients had thoracic operations 
before transplantation. Three patients had one chest procedure 
(repair of ventricular septal defect, Mustard procedure, and 
right lower lobectomy in one patient each), and one patient had 
two prior operations (pulmonary artery banding at the age of 5 
months and Mustard procedure at the age of 3 years). 
Recipient selection. All children in this series had end-stage 
parenchymal or vascular lung disease that significantly affected 
their lifestyle. School-age children had either curtailed or 
discontinued school activity. All candidates with primary pul-
monary hypertension had near-systemic or suprasystemic pul-
monary artery pressures with associated signs of right-sided 
heart failure. Fifty percent (n = 10) of our patients werereceiv-
ing supplementary oxygen and one patient was dependent on a 
ventilator before transplantation. Profound cyanosis, clubbing, 
and polycythemia were present in all candidates with congen-
ital heart disease and pulmonary arteriovenous malformation. 
Five (20%) patients were receiving prednisone at the time of 
transplantation, and although attempts were made to wean ste-
roids as tolerated, this was not considered a contraindication to 
lung transplantation. Likewise, we cautiously increased our 
experience in patients with previous thoracic and cardiac 
surgery. In candidates whose disease process affected their air-
way function, pulmonary function tests-first-second forced 
expiratory volume (FEY j ), forced vital capacity (FVC), and 
forced expiratory flow (FEF25-27 )-were less than 30% of pre-
dicted normal values for age, height, and weight. Whenever 
possible, an exercise study was performed with pulse oximetry, 
both as a measure of exercise-induced hypoxia and also as an 
objective test for follow-up of the candidate accepted for trans-
plantation. 
Implantation techniques. The implantation techniques for 
heart-lung (n = 11),2 double lung (n = 2),3 sequential bilateral 
single lung (n = 6),4 and single lung (n = 1)5 transplantation 
have been previously described and were used in this series of 
patients without significant changes. We no longer wrap the 
tracheal or bronchial anastomoses with omentum, and we have 
used a telescoping airway anastomosis with polypropylene 
suture. Only one of the six patients undergoing sequential bilat-
eral single lung transplantation required cardiopulmonary 
bypass because of profound hypoxemia. This 10-year-old boy 
with pulmonary arteriovenous malformation and prior right 
upper lobectomy had an arterial oxygen saturation of 46% under 
anesthesia before the skin incision. 
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Fig. 2. Pediatric lung transplantation, 1985 to 1992. A-V, Arteriovenous. 
Donor evaluation and lung preservation. Our criteria for 
acceptance of a lung donor has evolved over the past decade. In 
this series, the cause of brain death of the donors was equally 
distributed among gunshot wound to the head, blunt head trau-
ma resulting from vehicular accidents, and intracerebral hem-
orrhage or tumor. The opportunity to observe the clinical course 
of a cadaveric donor over 24 to 72 hours of hospitalization was 
not always feasible but has been invaluable in discerning the 
quality oflungs for donation. Not only were a clear chest radio-
graph and an arterial oxygen tension of 400 torr on 100% oxy-
gen in the organ donor desirable, the trend of these pulmonary 
variables, over time, was critical. Donor sputum Gram stain and 
culture rarely precluded lungs for consideration, with the 
exception of moderate growth of yeast. All donors underwent 
bronchoscopic and visual inspection of the lungs at the time of 
harvest. Pulmonary contusion, chest tubes, and tracheostomies 
were relative and not absolute contraindications to lung pro-
curement.6 
All lung donors received intravenous methylprednisolone, 
clindamycin, and ceftazidime, as well as aerosolized gentami-
cin.? The first two donors in this series were transferred to CRP 
from other centers and underwent core-cooling for procurement 
in 1985. Although we first described long-distance lung pro-
curement and transport with an ex vivo autoperfused heart-lung 
preparation,8 this technique was used in only one patient in this 
series. Four donors underwent core-cooling and 15 had rapid 
high-volume pulmonary flushing with either Euro-Collins 
(n = 4) or University of Wisconsin solution (n = 11). Care was 
always taken to adequately vent the left side of the heart during 
lung flushing, which we accomplished by first administering 
cardioplegic solution with the left atrial appendage opened and 
then transecting the aorta to assure a pulmonary venous pres-
sure of zero during the infusion. We have found it convenient to 
use a small roller-head pump and heat exchanger to deliver the 
60 ml/kg flush solution at 40 C. Gentle hand ventilation was 
maintained during the pulmonary infusion. The flushed lungs 
were then transported, three-fourths inflated with oxygen, in the 
iced flush solution. The details of our explantation technique 
have been previously described.9 
Immunosuppression. All patients in this series were treated 
with triple-drug immunosuppression. Nine patients (group 1) 
had cyclosporine and 11 patients (group 2) had FK 506 as the 
basis of their immunosuppressive protocol. One patient, includ-
ed in group 2, was begun on the cyclosporine regimen but was 
switched to FK 506 at 12 weeks after transplantation because 
of persistent rejection, severe hirsutism, and hypertension. Aza-
thioprine, 4 mg/kg intravenously, was begun before transplan-
tation and continued after transplantation, either intravenously 
or orally, at a dosage of2 mg/kg per day. Azathioprine was dis-
continued or the dose was decreased with associated neutrope-
nia. Methylprednisolone, 10 mg/kg, was given intraoperatively 
and 5 mg/kg, in three divided doses, on the first postoperative 
day. Thereafter, patients received prednisone, 0.1 mg/kg per 
day, by mouth. Four patients in group 1 received rabbit 
antithymocyte globulin, 1.5 mg/kg per day intramuscularly, for 
5 days as immunoprophylaxis; no patients in group 2 received 
rabbit antithymocyte globulin. In group 2, steroid weaning was 
begun 6 months after transplantation. 
Cyclosporine or FK 506 was begun in the postoperative peri-
od as an intravenous infusion and was continued for 48 to 72 
hours. When gastrointestinal function returned, immunosup-
pressive drugs were administered orally. In group 1, the intra-
venous cyclosporine dosage was 1.5 mg/kg per day. The oral 
dosage of cyclosporine was 5 mg/kg per day, in two divided 
doses. The daily dose was adjusted to attain a trough level of 200 
to 250 ng/m! by plasma high-performance liquid chromatogra-
phy. In group 2 patients, the intravenous FK 506 induction dos-
age was 0.05 mg/kg per day and the oral maintenance dosage 
was 0.3 mg/kg per day in two divided doses. The oral dose of 
FK 506 was targeted for a serum trough level of 1 to 2 ng/ml 
(as measured by the enzyme-linked immunosorbent assay tech-
nique of Tamaura and associates lO). 
Monitoring and treatment of rejection. All patients in this 
series had bronchoscopic treatment with bronchoalveolar lavage 
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Fig. 3. Pediatric lung transplantation, survival-1985 to 1992. 
approximately 2 and 4 weeks after transplantation. Since 1989, 
transbronchial biopsy has been performed at the time of the 
lavage. The lavage specimen was evaluated for total cell count 
and differential, microbiologic assays, and immunologically 
with a donor-specific primed lymphocyte test (PLT).II Patients 
received empiric or "clinical" treatment of rejection only during 
the first 7 to 10 days after transplantation if clinical and radio-
graphic findings were both consistent with lung rejection and 
there was no evidence of infection. 
Treatment of lung rejection since 1989 has been based on 
standardized histologic criteria. 12 Acute rejection, grade 2 to 4, 
and chronic airway rejection with active bronchiolitis obliterans 
were first treated with intravenous methylprednisolone, 10 
mg/kg per day, for 3 consecutive days. Refractory or severe 
episodes or associated obliterative bronchiolitis were treated 
with courses of rabbit antithymocyte globulin or Minnesota 
antilymphocyte globulin. 
Outpatient evaluation consisted of clinic visits, blood tests, 
chest radiographs, pulmonary function tests, bronchoalveolar 
lavage, and transbronchial biopsy. Although follow-up visits 
were individualized on the basis of clinical and rejection histo-
ry, they were generally scheduled for 2, 6, and 12 weeks after 
discharge. Thereafter, regular follow-up was every 3 to 4 months 
for the first year after transplantation and every 4 months for 
subsequent years. All patients were instructed in the use of and 
discharged home with hand-held spirometers. When able, 
recipients used a portable spirometer to record daily measure-
ments of airflow. A persistent 10% fall in FVC or FEV l initi-
ated a return visit to CHP for bronchoalveolar lavage and 
transbronchial biopsy. A recent cytomegalovirus infection or 
persistent elevation in primed lymphocyte test results increased 
our surveillance and concern for lung rejection. 
Patients with heart-lung transplants had one endomyocardial 
biopsy before discharge. Thereafter, endomyocardial biopsy 
was done at year 1 and every 2 years thereafter, with complete 
left and right heart catheterization. All heart biopsy specimens 
were graded according to standardized histologic criteria. 13 
Monitoring for infection and prophylaxis. All patients were 
observed by a specialist in infectious disease. Before transplan-
tation, titers for hepatitis A, B, C, and D, herpesvirus, Epstein-
Barr virus, human immunodeficiency virus, Toxoplasma, and 
cytomegalovirus were performed on all donors and recipients. 
Skin testing for tuberculosis and anergy was routine. Sputum 
cultures were obtained every 3 months from candidates with 
cystic fibrosis to guide perioperative antimicrobial prophylaxis. 
Unless surveillance cultures suggested otherwise, periopera-
tive antibiotics consisted of clindamycin, ceftazidime, and 
amphotericin B. They were maintained for 48 hours after the 
operation and were adjusted to cover bacterial sensitivities 
obtained from the donor culture. Patients with cystic fibrosis 
always received an aminoglycoside for 10 to 14 days. Since 
1989, our prophylactic strategy for cytomegalovirus has includ-
ed intravenous ganciclovir for 4 weeks, followed by acyclovir 
(650 mg/m2 per day) for 6 months. Only cytomegalovirus-neg-
ative blood products were administered. Oral mycostatin and 
trimethoprim sulfamethoxazole were given to all patients after 
their transplant operation. Surveillance cultures from the tra-
chea or bronchoalveolar lavage fluid were obtained on patients 
who remained dependent on a ventilator for more than 72 hours 
and at the time of routine transbronchial biopsy. Serologic fol-
low-up was performed on all seronegative patients and on 
seropositive patients to monitor for evidence of reactivation. 14 
Results 
Survival and mortality. Sixteen of the 20 (80%) 
patients in this series survived. The perioperative mortal-
ity (45 days after transplantation) was 20%. There have 
been no late deaths. An overview of the survival and fol-
low-up is depicted in Fig. 3. The mean follow-up was 2 
years and the longest follow-up, 6Vz years. Eleven of the 
lung transplants in this series were done within the last 
year, and nine (82%) of the patients have survived. There 
were no deaths and no cases of postoperative bleeding in 
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the four patients who had had prior thoracic operations. 
The four deaths in this series are detailed as follows: 
CASE 1. Our first pediatric heart-lung transplant recip-
ient (June 1985) was a 14-year-old girl from Oklahoma 
who had congenital heart disease (double-inlet left ven-
tricle, hypoplastic right ventricle with discordant ventric-
uloarterial connection, and transposition of the great 
arteries). She returned to the hospital on the day of dis-
charge (postoperative day 20) with a mild cough, short-
ness of breath, and a diffuse interstitial pulmonary infil-
trate. Bronchoalveolar lavage failed to reveal a 
pathogenic organism or cell differential suggestive of 
infection. She was treated with intravenous methylpred-
nisolone for 3 days. She died on postoperative day 43, 
despite extracorporeal membrane oxygenation support, 
of cytomegalovirus pneumonia. Lung procurement and 
transportation were done with the autoperfused heart-
lung block. Immunosuppressive drugs included cyclo-
sporine, azathioprine, and steroids. This patient's course 
and treatment antedated our routine use of intravenous 
ganciclovir and transbronchial biopsy. 
CASE 2. Our second pediatric recipient was a 12-year-
old girl with primary pulmonary hypertension who under-
went heart-lung transplantation in July 1985. She died on 
the second postoperative day of primary organ nonfunc-
tion, despite initial adequate arterial oxygenation. The 
donor had been injured in a motor vehicle accident and 
had had long bone and pelvic fractures. Postmortem 
examination of the lungs revealed bone and cartilage 
emboli in the pulmonary vasculature. Lung preservation 
in this case was core-cooling of a donor transported to our 
center. Immunosuppressive therapy comprised cyclospor-
ine, azathioprine, and steroids. 
CASE 3. A 13-year-old girl with cystic fibrosis had 
waited more than I year for lung transplantation when 
she had a severe pulmonary exacerbation with a temper-
ature of 1040 F in July 1991, necessitating intubation and 
mechanical ventilation. She underwent double lung trans-
plantation on the third day of mechanical ventilation. 
Cultures of blood drawn before transplantation subse-
quently grew two Pseudomonas organisms. Although 
initial lung function was excellent, she was never extu-
bated and died on postoperative day 30 of disseminated 
aspergillosis despite continued prophylaxis with intrave-
nous amphotericin B. Lung preservation was by flushing 
with University of Wisconsin solution and ischemic times 
were 390 minutes and 420 minutes. Immunosuppressive 
agents included FK 506, azathioprine, and steroids. 
CASE 4. A 1 O-year-old girl with cystic fibrosis had dou-
ble lung transplantation in February 1992. She was extu-
bated on postoperative day 2 with excellent oxygenation 
and a clear chest radiograph. She required reintubation 
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on postoperative day 10, and results of both transbron-
chial biopsy and open lung biopsy were consistent with 
diffuse alveolar damage and no acute cellular rejection. 
The patient had a tracheostomy and her condition began 
to improve slowly. However, an adenoviral pneumonia 
developed and she died on postoperative day 45. Lung 
preservation was by flushing with University of Wiscon-
sin solution and ischemic times were 213 minutes and 333 
minutes. Immunosuppressive therapy comprised FK 506, 
azathioprine, and steroids. 
Rejection. Despite the advent of standardized nomen-
clature for the histologic features of lung rejection and 
retrospective reclassification of all lung biopsy specimens 
in this series, we have chosen to define rejection as a 
"treated" episode. There have been no deaths as a result 
of rejection. No patient had a panel reactive antibody 
greater than 10%. All retrospective crossmatches were 
negative. The mean number of treated episodes of rejec-
tion in the 14 patients observed for more than 100 days 
was 1.4 at less than 30 days, 0.5 at 30 to 90 days, and 1.4 
at more than 90 days. The mean number of days to the 
first treated rejection episode was 28 days and to the sec-
ond episode, 100 days. There was no statistically signif-
icant difference in these parameters of rejection between 
patients treated with cyclosporine and those treated with 
FK 506. No patient in the FK 506 group has required 
treatment with any antilymphocyte agent. Six of seven 
patients in the cyclosporine group have required an aver-
age of two treatments per patient, with mouse antilym-
phocyte globulin, rabbit antithymocyte globulin, or 
OK T3. However, only three of these patients received the 
antilymphocyte therapy within the first year after trans-
plantation. 
Four (25%) patients in this series have obliterative 
bronchiolitis. Two of these patients have mild obliterative 
bronchiolitis with only moderate diminution in pulmo-
nary function at 4 and 5 years after transplantation. The 
other two patients have obliterative bronchiolitis and 
chronic rejection associated with substantial reduction in 
small airway function, although both patients remain 
quite active. One patient with mild obliterative bronchi-
olitis and one with obliterative bronchiolitis and chronic 
rejection have associated Pseudomonas bronchitis. 
Cardiac function has been excellent in all heart-lung 
recipients. There have been no significant episodes of car-
diac rejection with the exception of one patient who had 
grade 3B rejection after reduction in immunotherapy for 
the treatment of posttransplantation Iymphoproliferative 
disease. Coronary angiograms have shown no abnormal-
ities. 
Spirometry. Six months after the operation, the aver-
age FEY1 was 82% of predicted (range 66% to 111 %), 
3 4 2 Armitage et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
February 1993 
Fig. 4. Transesophageal echocardiogram, posttransplantation day 4, demonstrating right pulmonary venous 
thrombus with extension into the left atrium. T, Thrombus; LA, left atrium. 
FVC was 89% of predicted (range 72% to 108%), and 
FEF25-75 was 72% of predicted (range 54% to 98%). 
Patients at I-year follow-up showed continued improve-
ment in these measures of pulmonary function. Only two 
patients with obliterative bronchiolitis had FEV I, FVC, 
or FEF25-75 of less than 80% of predicted normal values. 
The patient with a single lung transplant was excluded 
from these figures; she has had three courses of intrave-
nous steroids and one course of rabbit antithymocyte 
globulin in 9 months. Her FEV 1 is 64%, FVC 57%, and 
FEF25-75 77% of predicted normal values. 
Infection. Infection caused two deaths, one as a result 
of cytomegalovirus pneumonia and the other as a result 
of aspergillosis. There were four other major infections 
among the 16 survivors. (I) Cytomegalovirus pneumonia 
occurred in a cytomegalovirus-negative recipient receiv-
ing a cytomegalovirus-positive donor organ, despite 4 
weeks of intravenous ganciclovir after transplantation. 
(2) A pneumococcal pneumonia developed 2 days after a 
bronchoalveolar lavage and transbronchial biopsy but 
quickly resolved with intravenous antibiotics. (3) A res-
piratory syncytial viral pneumonia occurred in one young 
girl who required prolonged intubation; this resolved with 
ribavirin therapy. (4) Hepatitis caused by Epstein-Barr 
virus developed 2 years after transplantation in an 
Epstein-Barr-positive recipient and resolved with reduc-
tion in immunosuppression. There were three minor 
infections: One patient had coxsackie virus infection and 
two patients had mild bacterial bronchitis. Six cytomeg-
alovirus-negative recipients received cytomegalovirus-
positive donor organs, and as yet only one patient has 
cytomegalovirus disease. Two patients had cytomegalo-
virus-positive bronchoalveolar lavage studies, but the 
infection resolved with intravenous ganciclovir treatment. 
Posttransplantation Iymphoproljferative disease. 
Two ( 12.5%) Epstein-Barr-negative recipients have post-
transplantation lymphoproliferative disease. In both 
patients the disease became apparent in the lung during 
the third month after transplantation, as a diffuse infil-
trate in one and as multiple pulmonary nodules associ-
ated with tonsiJlopharyngitis and hepatosplenomegaly in 
the other. Each patient had an associated infection, res-
piratory syncytial virus and cytomegalovirus from a 
bronchoalveolar lavage, respectively. These patients had 
reduction in immunotherapy and recovered with no 
recurrent disease. The first patient had received rabbit 
anti thymocyte globulin immunoprophylaxis and cyclo-
sporine-based' triple-drug therapy and the other received 
FK 506-based triple-drug therapy without an antilym-
phocyte preparation. 
Other complications. A summary of the complica-
tions observed in this group is outlined in Table I. Post-
operative problems ranged from minor drug-related tox-
icities to those necessitating operative intervention. One 
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Fig. 5. Transesophageal echocardiogram after repair of right pulmonary venous anastomosis under cardiopulmo-
nary bypass, posttransplantation day 5. LA, Left atrium. 
patient who had right-sided pulmonary venous thrombo-
sis was reintubated on postoperative day 4 and the diag-
nosis of pulmonary venous thrombosis was made by 
transesophageal echocardiography (Figs. 4 and 5). At 
reoperation the anastomosis appeared usual except for 
obstructing thrombus. After revision, the patient was 
treated with intravenous heparin for 4 weeks and, to date, 
the problem has not recurred. The bronchial stenosis, 
which was mild, was due to a telescoped left main bron-
chial cartilage and has not required treatment. The uter-
ine and nasal bleeding were systemic manifestations of 
capillary hemangiomatosis in a patient with pulmonary 
arteriovenous malformation. The gastric atony was due to 
vagal nerve paresis, which occurred during sequential 
bilateral lung transplantation. After the patient's dis-
charge from the hospital, gastric outlet obstruction devel-
oped, which necessitated readmission and pyloroplasty. 
The average stay in the intensive ca re unit was 12 days 
(range I to 90 days); nine of 16 patients stayed less than 
I week. The average period of postoperative intubation 
was 6 days (range I to 45 days); nine of 16 patients were 
intubated 3 days or less. 
Discussion 
Overall, we have been gratified with our results in these 
20 patients: an 80% survival and no late deaths at a mean 
follow-up of 2 years. In many respects these children were 
Table I. ComplicatiOns 
No. % 
Postoperative bleeding 3/20 15% 
Phrenic paresis 2/ 20 10% 
Bronchial stenosis 1/ 16 6% 
Pulmonary vein thrombosis 1/16 6% 
Hypertension 4/16 25% 
Group I (cyclosporine) 4/ 8 50% 
Group 2 (FK506) 0/8 0% 
Hirsutism (cyclosporine) 1/16 6% 
Gingival hyperplasia (cyclosporine) 1/ 16 6% 
Uterine/ nasal bleeding 1/16 6% 
Gastrointestinal 2/16 12% 
Pathology Treatment Postopera live 
day 
Appendicitis Appendectomy 35 
Gastric atony Pyloroplasty 40 
the beneficiaries of the difficult lessons learned in the are-
na of adult lung transplantation. An additional advantage 
for children is their youth-both their own youth and tha t 
of the donor. Compared with results in our adult series, 
primary nonfunction because of preservation injury was 
notably absent as a complication in this group, perhaps a 
testament to the higher threshold for ischemic injury of 
pediatric tissues. 
We did not consider prior thoracotomy or sternotomy 
an absolute contraindication to lung transplantation. For 
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example, one patient with pulmonary arteriovenous mal-
formation underwent right lower lobectomy at 3 years of 
age and coil embolization of the right upper lobe at 4 and 
5 years of age. This boy weighed 16 kg and was 117 cm 
tall. He had been wheelchair-bound and dependent on 
supplementary oxygen for 2 years and had never attend-
ed school despite his age of 10 years. Three other patients, 
as previously noted, had prior cardiac operations. There 
were no reoperations for bleeding and no deaths in this 
group. A prior thoracic operation is not an absolute con-
traindication to lung or heart-lung transplantation; it is 
advisable, however, to accrue experience in patients 
without prior thoracic operations before undertaking the 
additional challenges involved in reoperation. Another 
patient in our series was of particular note because of her 
pretransplantation status. A l5-year-old girl had received 
a bone marrow transplant from her sister (human leuko-
cyte antigen-identical and mixed lymphocyte culture-
compatible) at the age of 7 years for aplastic anemia. Her 
course after bone marrow transplantation was compli-
cated by severe graft-versus-host disease, pneumonia, 
respiratory insufficiency, dependence on mechanical ven-
tilation, and tracheostomy. Eight years later the FEVI, 
FVC, and FEF25-75 were all 10% to 20% of predicted, and 
she was dependent on supplementary oxygen. Her bone 
marrow function was normal and she was accepted for 
lung transplantation. 
Perhaps the most important lessons to be learned are 
those gleaned from our failures. Two of the four patients 
who died had cystic fibrosis. Although cystic fibrosis, as 
an indication for lung transplantation, represents an 
increasing population, in our opinion these patients are 
particularly challenging candidates and represent a high-
risk group. The evaluation of patients with cystic fibrosis 
can be difficult, because the course of their pulmonary 
disease waxes and wanes; however, when a patient with 
cystic fibrosis becomes dependent on supplementary oxy-
gen, it is reasonable to begin the evaluation for lung 
transplantation. Along with the problems associated with 
all other patients with end-stage lung disease, patients 
with cystic fibrosis have tracheal colonization with organ-
isms that are difficult to control with antibiotics. These 
include Pseudomonas aeruginosa, Pseudomonas cepa-
cia, and frequently (60%) Aspergillus. Patients with cys-
tic fibrosis also commonly are malnourished and have 
chronic sinusitis and osteoporosis. Indwelling intravenous 
or enteral catheters are frequently in place at the time of 
transplantation. Therapy directed toward each individu-
al patient's microbial colonization is mandatory. Com-
passionate but emotional decisions designed to salvage 
particularly those patients in extremis should be avoided. 
The third death in our series was due to occult pulmonary 
emboli in the donor; when present, this is a lethal compli-
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cation for the recipient. In our experience with nearly 200 
lung donors, four other such cases were observed, three 
with thrombotic emboli and one with a brain embolus. 15 
The fourth death in our series was due to cytomegalovi-
rus pneumonia, in part the result of ill-advised empiric 
treatment of rejection without histologic confirmation. 
This occurred before our routine use of transbronchial 
biopsy and before ganciclovir was available. 
We strongly concur with the national trend toward the 
use of single and double lung procedures whenever pos-
sible. Donor organs are thus used more efficiently and 
benefit a greater number of recipients. The first double 
lung transplantation performed in a child was done at 
CHP (January 1989) in a 15-year-old girl from Seattle 
with pulmonary arteriovenous malformation. The opera-
tion was done with cardiopulmonary bypass and trache-
al, left atrial, and pulmonary arterial anastomoses. Our 
preferred technique for double lung transplantation is 
that of bilateral sequential single lung transplantation, for 
which we perform telescoped bronchial anastomoses 
through a transthoracic incision. Our second double lung 
transplantation was in a child with primary pulmonary 
hypertension. Dramatic resolution of right ventricular 
dilatation and hypertrophy was observed after transplan-
tation. Eight of our adult patients have done well after 
repair of their congenital heart defects at the time of dou-
ble lung transplantation. Clearly, this approach can be 
applied to the pediatric group as well. Only complex forms 
of congenital heart disease necessitate heart-lung trans-
plantation, but when a heart-lung block is available and 
no heart candidate is identified, we have chosen to use 
heart-lung transplantation. The answers and long-term 
results are not yet available to questions regarding the 
differences in peak exercise capacity, right-sided heart 
function, pulmonary pressures, prevalence of obliterative 
bronchiolitis, and survival in patients with single versus 
double lung transplants; multicenter trials directed at 
specific patient groups are needed. 
Infection is a constant threat to the lung transplant 
recipient, and in this pediatric group viral infections posed 
the greatest dangers. All recipients now receive intrave-
nous ganciclovir for 4 weeks after transplantation and 
high-dose oral acyclovir for 6 months to protect them 
against cytomegalovirus. Conclusions regarding the 
effectiveness of this treatment strategy will require a 
larger patient group and longer follow-up. Cytomegalo-
virus is not just an infectious threat; rather, it places the 
recipient at significant risk of future rejection because of 
up-regulation of immune mechanisms systemically and in 
the graft, locally.16 In addition, Epstein-Barr virus is of 
particular concern to the pediatric lung recipient. Wel7 
have shown, during a decade of heart and lung trans-
plantation, that both the pediatric organ recipient and the 
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lung recipient are at increased risk for the development of 
posttransplantation lymphoproliferative disease. It is thus 
not surprising to observe a 12.5% prevalence of posttrans-
plantation lymphoproliferative disease in our pediatric 
lung transplant group. We were fortunate to have recog-
nized the disease and successfully treated both recipients 
in whom posttransplantation lymphoproliferative disease 
was diagnosed. It is helpful to remember that this disease 
is most likely to appear in the lung of a lung recipient and 
usually occurs within the first posttransplantation year. 
Other infections have been relatively few in this group. 
The trial of FK 506 in the pediatric group was begun 
because of the dramatic immune and therapeutic advan-
tage this agent had in the pediatric cardiac transplant 
recipients. l8 Weare hopeful that the improved freedom 
from rejection, steroid-sparing effects, and lack of hyper-
tension, hirsutism, gingival hyperplasia, and facial bone 
growth abnormalities will be realized by the pediatric 
lung recipients as well. The FK 506 trial was also designed 
to determine if obliterative bronchiolitis may be less 
prevalent under the influence of this potent immunosup-
pressive macrolide. At this early juncture, we have not 
seen obliterative bronchiolitis in any patient receiving FK 
506. Because of the relatively short follow-up in our FK 
506-treated patients, direct comparisons between cyc1o-
sporine and FK 506 are oflittle value. It is safe to say that, 
under both protocols, most patients will have one or two 
episodes of acute lung rejection in the first 90 days. We 
have, however, successfully avoided the use of antilym-
phocyte agents thus far in the FK 506 group. 
We stand at the beginning of an era when lung trans-
plantation will bring new hope, life, and joy to young 
patients with end-stage lung disease. We hope this small 
series raises new questions and challenges to those 
involved in the field. Clearly, we can all broaden the scope 
of candidates who will benefit from lung transplantation 
and we should continue the endeavor to maximally use the 
available lung donor pool. 
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Discussion 
Dr. R. Morton Dolman III (Minneapolis, Minn.). Dr. 
Armitage, I am amazed at your results. Pittsburgh continues to 
show tremendous leadership in the field of thoracic organ 
replacement. You mention a group of eight patients who had 
Eisenmenger's physiology on whom you performed double lung 
transplantation in conjunction with repair of the cardiac defects. 
Could you extrapolate this to your pediatric population and tell 
us what congenital heart defects you consider repairable at the 
time of concomitant lung replacement? 
I would also like some advice on redo operations. We are see-
ing, as you are, I am sure, many patients who have, until 
recently, been thought to be unable to have another operation 
because of multiple previous procedures for congenital heart 
disease. With the success that you and others have enjoyed in 
this area, can we reconsider these patients? Where do we draw 
the line? Is aprotinin going to have a role and how do you envi-
sion the future in this area? We have now performed 11 trans-
plants in seven children. Six of seven have been long-term sur-
vivors, but we have observed the need for retransplantation in 
four of those patients. One patient has also had a recurrence of 
his original disease. Obliterative bronchiolitis has developed in 
two of the six, so we do see an approximate equivalent incidence 
to that observed in our adult population. Could you address 
these questions? 
Dr. Hani Shennib (Montreal, Quebec, Canada). You are 
achieving impressive results with pediatric transplantation. As 
a result of the initial poor results reported in pediatric trans-
plantations, we reviewed our own data at the joint Marseille-
Montreal lung transplant program and presented our data at the 
last Society of Thoracic Surgeons meeting. We showed that a 
78% I-year survival can be obtained after bilateral lung trans-
plantation in children, so I am very pleased to see you confirm-
ing our results. 
I have a question with regard to your conclusion that patients 
with cystic fibrosis constitute a high-risk group. Perhaps the few 
patients with cystic fibrosis that you have treated in the pediat-
ric population have been at particularly high risk because of 
their need for ventilatory support, because of resistant bacteria, 
or because of their need for high-dose steroids. Almost all of the 
patients in our series have had cystic fibrosis, except for one 
patient with complex congenital heart disease. I would like to 
know why you state that patients with cystic fibrosis are at 
higher risk and how you explain the discrepancy between our 
report and yours. I would also like to get your advice on what 
operation you would do, and for what indications, in patients 
having complex congenital heart disease involving transposition. 
Are there any technical precautions you would advise us to use? 
The Journal of Thoracic and 
Cardiovascular Surgery 
February 1993 
Dr. Armitage. In the adult population we have done seven 
double-lung transplantations and one single lung transplanta-
tion at the time of a corrective procedure on the heart or great 
vessels. Most of these anomalies were atrial septal defect, ven-
tricular septal defect, and patent ductus. The patient with patent 
ductus can be difficult to treat. The duct is usually quite large 
and the pulmonary pressures are usually quite high. Obtaining 
control of that ductus and clamping it before the start of 
cardiopulmonary bypass can be difficult. 
Where does the limit lie as to what congenital defect can be 
repaired at the time of double lung transplantation? I cannot say 
for sure. We have mainly addressed the more routine problems: 
atrial and ventricular septal defect and patent ductus. Clearly 
transpositions can be repaired. Our experience in children is that 
although heart-lung blocks are difficult to obtain for the child, 
they are not as difficult as in the adult, because there are not as 
many children needing a donor heart. Occasionally we are 
offered two lungs in a case in which there is no adequate recip-
ient for the heart. If we have the opportunity, we prefer heart-
lung transplantation in a child if the organs are available and we 
are not depriving anyone else. Clearly, if there is a child who 
needs that heart, we use just the lungs. 
Our preferred technique in double lung transplantation is 
bilateral sequential single lung transplantation with telescoping 
bronchial anastomoses. Our one case of bronchial stenosis 
occurred in a 10-year-old patient with cystic fibrosis and a long, 
small left bronchus. I would concur with the previous comment 
to be careful with that technique in a child. 
Which redos to do? Initially, we agonized over doing the redos 
at all. We became a little braver as we went along. The oper-
ations in both the children with Mustard procedures were a lit-
tle bit difficult. One of them required end-to-end inferior and 
superior vena caval anastomoses. The baffle calcified, and it was 
difficult to identify the phrenic nerve. Those are the kind of 
problems encountered in patients having had a prior operation. 
They frequently require a little longer ventilation if phrenic 
nerve paresis develops. 
I do not think that all patients with cystic fibrosis are at high 
risk, but some are. They have multiple antibiotic-resistant 
organisms; they are malnourished; they have osteoporosis; they 
have indwelling catheters. Those are all issues that we deal with 
and struggle with to get these patients through. I believe the 
overall world survival in cystic fibrosis patients with lung, 
heart-lung, or double lung transplantation is about 65%. That 
is in all centers. These patients will certainly represent an 
increasing candidate population, but I still believe that it is dif-
ficult to get them through the procedure. 
